Dulac Edward J III's Form 4 filing
Fate Therapeutics IncFATE · filed Aug 19, 2022
- Accession no.
- 0001209191-22-046929
- Filed
- Aug 19, 2022
- Trade date
- Aug 18, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $153.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dulac Edward J IIICIK 0001821530 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2022 | Common Stock | SSaleDisposed | −4,703 | $29.75F2 | −$139,914.25 | 137,233 | Direct | |
| Aug 18, 2022 | Common Stock | SSaleDisposed | −432 | $30.41 | −$13,137.12 | 136,801 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $29.29 to $30.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2.
Referenced by the price of 1 transaction in Table I.